ALIVUS vs VENUSREM: Stock Comparison
Alivus Life Sciences Limited is the larger company by market capitalisation. Alivus Life Sciences Limited shows a higher net margin, while Venus Remedies Limited shows a lower P/E, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
ALIVUS leads 2; VENUSREM leads 6 of 8
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ALIVUS | VENUSREM |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | ALIVUS | VENUSREM |
|---|---|---|
| Live Price | ₹1,350.9 | ₹1,797.5 |
| Day Change | -1.39% | 4.8% |
| Volume | 69,399 | 2.46 L |
| 52-Week High | ₹1,418 | ₹1,800.8 |
| 52-Week Low | ₹819 | ₹424 |
| Distance from 52W High | -4.73% | -0.18% |
Valuation
| Metric | ALIVUS | VENUSREM |
|---|---|---|
| Market Cap | ₹16,58,519.49 L Cr | ₹2,306 Cr |
| P/E Ratio | 27.35x | 20.1x |
| P/B Ratio | 4.95x | 3.52x |
| EPS | ₹49.04 | ₹76.93 |
| Book Value | ₹271.02 | ₹444.63 |
| Dividend Yield | 0.37% | 0.56% |
Growth
| Metric | ALIVUS | VENUSREM |
|---|---|---|
| Revenue Growth (TTM YoY) | 6.1% | 33% |
| EPS Growth (TTM YoY) | 14.5% | 126.4% |
| Qtr Sales Growth | — | 21.4% |
| Qtr Profit Growth | — | 687% |
Profitability & Leverage
| Metric | ALIVUS | VENUSREM |
|---|---|---|
| ROE | — | 15.48% |
| ROCE | — | 11.1% |
| Net Margin | 22.05% | 13.35% |
| Operating Margin | 31.4% | 17.44% |
| Debt to Equity | — | 0x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | ALIVUS | VENUSREM |
|---|---|---|
| Promoter Holding | 74.87% | 41.76% |
| FII Holding | 5.54%▲ 0.25 pp | 2.92%▲ 0.12 pp |
| DII Holding | 7.18%▼ 0.1 pp | 0.89%▼ 0.31 pp |
| Public Holding | 12.41%▼ 0.15 pp | 54.43%▲ 0.19 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Alivus Life Sciences Limited and Venus Remedies Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.